Molecular imaging of breast cancer

Breast

Volumn 18, Issue SUPPL.3, 2009, Pages

  Munnink, T H Oude ^a   Nagengast, W B ^a   Brouwers, A H ^a   Schroder C P ^a   Hospers, G A ^a   Hooge, M N Lub de ^a   van der Wall, E ^b   van Diest, P J ^b   de Vries, E G E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Breast cancer; Molecular imaging; Positron emission tomography; Single photon emission computed tomography; Staging

Indexed keywords

3' FLUOROTHYMIDINE F 18; BEVACIZUMAB ZR 89; DNA; ENDOSTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ESTROGEN RECEPTOR; FIBRONECTIN; FLUORODEOXYGLUCOSE F 18; HORMONE RECEPTOR; MONOCLONAL ANTIBODY; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RADIOISOTOPE; SOMATOMEDIN C RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB ZR 89; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VITRONECTIN RECEPTOR;

ARTICLE; BREAST CANCER; CANCER STAGING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DNA SYNTHESIS; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; ISOTOPE LABELING; METASTASIS; MOLECULAR IMAGING; NON INVASIVE MEASUREMENT; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 71749112003     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(09)70276-0     Document Type: Article

References (111)

1. Carney P.A., Miglioretti D.L., Yankaskas B.C., Kerlikowske K., Rosenberg R., Rutter C.M., et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 138 (2003) 168-175
2. Eckelman W.C., Reba R.C., and Kelloff G.J. Targeted imaging: an important biomarker for understanding disease progression in the era of personalized medicine. Drug Discov Today 13 (2008) 748-759
3. Mankoff D.A. Molecular imaging as a tool for translating breast cancer science. Breast Cancer Res 10 Suppl 1 (2008) S3
4. Mankoff D.A. A definition of molecular imaging. J Nucl Med 48 (2007) 18N 21N.
5. Fletcher J.W., Djulbegovic B., Soares H.P., Siegel B.A., Lowe V.J., Lyman G.H., et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 49 (2008) 480-508
6. Gambhir S.S. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2 (2002) 683-693
7. Endo K., Oriuchi N., Higuchi T., Iida Y., Hanaoka H., Miyakubo M., et al. PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients. Int J Clin Oncol 11 (2006) 286-296
8. Hayashi M., Murakami K., Oyama T., Domeki Y., Hagiwara S., Katsumata D., et al. PET/CT supports breast cancer diagnosis and treatment. Breast Cancer 15 (2008) 224-230
9. Buck A., Schirrmeister H., Kuhn T., Shen C., Kalker T., Kotzerke J., et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 29 (2002) 1317-1323
10. Crippa F., Seregni E., Agresti R., Chiesa C., Pascali C., Bogni A., et al. Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med 25 (1998) 1429-1434
11. Bos R., Der Hoeven J.J., van der Wall E., van der Groep P., van Diest P.J., Comans E.F., et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 20 (2002) 379-387
12. Hicks R.J., Binns D., and Stabin M.G. Pattern of uptake and excretion of (18)F-FDG in the lactating breast. J Nucl Med 42 (2001) 1238-1242
13. Bakheet S.M., Powe J., Kandil A., Ezzat A., Rostom A., and Amartey J. F-18 FDG uptake in breast infection and inflammation. Clin Nucl Med 25 (2000) 100-103
14. Barentsz J., Takahashi S., Oyen W., Mus R., De Mulder P., Reznek R., et al. Commonly used imaging techniques for diagnosis and staging. J Clin Oncol 24 (2006) 3234-3244
15. Samson D.J., Flamm C.R., Pisano E.D., and Aronson N. Should FDG PET be used to decide whether a patient with an abnormal mammogram or breast finding at physical examination should undergo biopsy?. Acad Radiol 9 (2002) 773-783
16. Tafra L., Cheng Z., Uddo J., Lobrano M.B., Stein W., Berg W.A., et al. Pilot clinical trial of 18F-fluorodeoxyglucose positron-emission mammography in the surgical management of breast cancer. Am J Surg 190 (2005) 628-632
17. Berg W.A., Weinberg I.N., Narayanan D., Lobrano M.E., Ross E., Amodei L., et al. High-resolution fluorodeoxyglucose positron emission tomography with compression ("positron emission mammography") is highly accurate in depicting primary breast cancer. Breast J 12 (2006) 309-323
18. Frangioni J.V. New technologies for human cancer imaging. J Clin Oncol 26 (2008) 4012-4021
19. Rosen E.L., Eubank W.B., and Mankoff D.A. FDG PET, PET/CT, and breast cancer imaging. Radiographics 27 Suppl 1 (2007) S215-S229
20. Hodgson N.C., and Gulenchyn K.Y. Is there a role for positron emission tomography in breast cancer staging?. J Clin Oncol 26 (2008) 712-720
21. Groheux D., Moretti J.L., Baillet G., Espie M., Giacchetti S., Hindie E., et al. Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer. Int J Radiat Oncol Biol Phys 71 (2008) 695-704
22. Fuster D., Duch J., Paredes P., Velasco M., Muñoz M., Santamaría G., et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol 26 (2008) 4746-4751
23. Eubank W.B., and Mankoff D.A. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med 35 (2005) 84-99
24. Mankoff D.A., and Eubank W.B. Current and future use of positron emission tomography (PET) in breast cancer. J Mammary Gland Biol Neoplasia 11 (2006) 125-136
25. Franc B.L., and Hawkins R.A. Positron emission tomography, positron emission tomography-computed tomography, and molecular imaging of the breast cancer patient. Semin Roentgenol 42 (2007) 265-279
26. Mahner S., Schirrmacher S., Brenner W., Jenicke L., Habermann C.R., Avril N., et al. Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer. Ann Oncol 19 (2008) 1249-1254
27. Minn H., and Soini I. [18F]fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer. Eur J Nucl Med 15 (1989) 61-66
28. Cook G.J., Houston S., Rubens R., Maisey M.N., and Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 16 (1998) 3375-3379
29. Nakai T., Okuyama C., Kubota T., Yamada K., Ushijima Y., Taniike K., et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging 32 (2005) 1253-1258
30. Shie P., Cardarelli R., Brandon D., Erdman W., and Abdulrahim N. Meta-analysis: comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastases in patients with breast cancer. Clin Nucl Med 33 (2008) 97-101
31. Yang W.T., Le-Petross H.T., Macapinlac H., Carkaci S., Gonzalez-Angulo A.M., Dawood S., et al. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat 109 (2008) 417-426
32. National Comprehensive Cancer Network (NCCN) Practice Guidelines in Oncology - v.1.2009. http://www.nccn.org/
33. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
34. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009) 228-247
35. Weber W.A. Positron emission tomography as an imaging biomarker. J Clin Oncol 24 (2006) 3282-3292
36. Kim S.J., Kim S.K., Lee E.S., Ro J., and Kang S. Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol 15 (2004) 1352-1357
37. Boellaard R., Oyen W.J., Hoekstra C.J., Hoekstra O.S., Visser E.P., Willemsen A.T., et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging 35 (2008) 2320-2333
38. Rousseau C., Devillers A., Sagan C., Ferrer L., Bridji B., Campion L., et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol 24 (2006) 5366-5372
39. Schwarz-Dose J., Untch M., Tiling R., Sassen S., Mahner S., Kahlert S., et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol 27 (2009) 535-541
40. Berriolo-Riedinger A., Touzery C., Riedinger J.M., Toubeau M., Coudert B., Arnould L., et al. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 34 (2007) 1915-1924
41. Smith I.C., Welch A.E., Hutcheon A.W., Miller I.D., Payne S., Chilcott F., et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18 (2000) 1676-1688
42. McDermott G.M., Welch A., Staff R.T., Gilbert F.J., Schweiger L., Semple S.I., et al. Monitoring primary breast cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat 102 (2007) 75-84
43. Dehdashti F., Flanagan F.L., Mortimer J.E., Katzenellenbogen J.A., Welch M.J., and Siegel B.A. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 26 (1999) 51-56
44. Mortimer J.E., Dehdashti F., Siegel B.A., Trinkaus K., Katzenellenbogen J.A., and Welch M.J. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 19 (2001) 2797-2803
45. Dehdashti F., Mortimer J.E., Trinkaus K., Naughton M.J., Ellis M., Katzenellenbogen J.A., et al. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 113 (2009) 509-517
46. Cachin F., Prince H.M., Hogg A., Ware R.E., and Hicks R.J. Powerful prognostic stratification by [18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy. J Clin Oncol 24 (2006) 3026-3031
47. Emmering J., Krak N.C., van der Hoeven J.J., Spreeuwenberg M.D., Twisk J.W., Meijer S., et al. Preoperative [18F]-FDG-PET after chemotherapy in locally advanced breast cancer: prognostic value as compared with histopathology. Ann Oncol 19 (2008) 1573-1577
48. Gil-Rendo A., Martinez-Regueira F., Zornoza G., Garcia-Velloso M.J., Beorlegui C., and Rodriguez-Spiteri N. Association between [(18)F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg 96 (2009) 166-170
49. Ueda S., Tsuda H., Asakawa H., Shigekawa T., Fukatsu K., Kondo N., et al. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol 38 (2008) 250-258
50. Been L.B., Elsinga P.H., de Vries J., Cobben D.C., Jager P.L., Hoekstra H.J., et al. Positron emission tomography in patients with breast cancer using (18)F-3′-deoxy-3′-fluoro-l-thymidine ((18)F-FLT) - a pilot study. Eur J Surg Oncol 32 (2006) 39-43
51. Smyczek-Gargya B., Fersis N., Dittmann H., Vogel U., Reischl G., Machulla H.J., et al. PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 31 (2004) 720-724
52. Pio B.S., Park C.K., Pietras R., Hsueh W.A., Satyamurthy N., Pegram M.D., et al. Usefulness of 3′-[F-18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 8 (2006) 36-42
53. Kenny L., Coombes R.C., Vigushin D.M., Al Nahhas A., Shousha S., and Aboagye E.O. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 34 (2007) 1339-1347
54. Salskov A., Tammisetti V.S., Grierson J., and Vesselle H. FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3′-deoxy-3′-[18F]fluorothymidine. Semin Nucl Med 37 (2007) 429-439
55. Breast Cancer Treatment (PDQ®) (2009). http://www.cancer.gov/cancertopics/pdq/treatment/breast/healthprofessional/
56. Kataja V., and Castiglione M. Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19 Suppl 2 (2008) ii11-ii13
57. Spataro V., Price K., Goldhirsch A., Cavalli F., Simoncini E., Castiglione M., et al. Sequential estrogen receptor determinations from primary breast cancer and at relapse: prognostic and therapeutic relevance. The International Breast Cancer Study Group (formerly Ludwig Group). Ann Oncol 3 (1992) 733-740
58. Kuukasjarvi T., Kononen J., Helin H., Holli K., and Isola J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 14 (1996) 2584-2589
59. Brunn R.B., and Kamby C. Immunohistochemical detection of estrogen receptors in paraffin sections from primary and metastatic breast cancer. Pathol Res Pract 185 (1989) 856-859
60. Normanno N., Di Maio M., De Maio E., De Luca A., de Matteis A., Giordano A., et al. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 12 (2005) 721-747
61. Yoo J., Dence C.S., Sharp T.L., Katzenellenbogen J.A., and Welch M.J. Synthesis of an estrogen receptor beta-selective radioligand: 5-[18F]fluoro-(2R,3S)-2,3-bis(4-hydroxyphenyl)pentanenitrile and comparison of in vivo distribution with 16alpha-[18F]fluoro-17beta-estradiol. J Med Chem 48 (2005) 6366-6378
62. Dehdashti F., Mortimer J.E., Siegel B.A., Griffeth L.K., Bonasera T.J., Fusselman M.J., et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 36 (1995) 1766-1774
63. Mintun M.A., Welch M.J., Siegel B.A., Mathias C.J., Brodack J.W., McGuire A.H., et al. Breast cancer: PET imaging of estrogen receptors. Radiology 169 (1988) 45-48
64. Peterson L.M., Mankoff D.A., Lawton T., Yagle K., Schubert E.K., Stekhova S., et al. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. J Nucl Med 49 (2008) 367-374
65. Mortimer J.E., Dehdashti F., Siegel B.A., Katzenellenbogen J.A., Fracasso P., and Welch M.J. Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res 2 (1996) 933-939
66. McGuire A.H., Dehdashti F., Siegel B.A., Lyss A.P., Brodack J.W., Mathias C.J., et al. Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med 32 (1991) 1526-1531
67. Linden H.M., Stekhova S.A., Link J.M., Gralow J.R., Livingston R.B., Ellis G.K., et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 24 (2006) 2793-2799
68. Hospers G.A., Helmond F.A., de Vries E.G., Dierckx R.A., and de Vries E.F. PET imaging of steroid receptor expression in breast and prostate cancer. Curr Pharm Des 14 (2008) 3020-3032
69. Moasser M.M. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26 (2007) 6469-6487
70. Hayes D.F., Thor A.D., Dressler L.G., Weaver D., Edgerton S., Cowan D., et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357 (2007) 1496-1506
71. Zidan J., Dashkovsky I., Stayerman C., Basher W., Cozacov C., and Hadary A. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 93 (2005) 552-556
72. Rasbridge S.A., Gillett C.E., Seymour A.M., Patel K., Richards M.A., Rubens R.D., et al. The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer 70 (1994) 335-341
73. Solomayer E.F., Becker S., Pergola-Becker G., Bachmann R., Kramer B., Vogel U., et al. Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients. Breast Cancer Res Treat 98 (2006) 179-184
74. Meng S., Tripathy D., Shete S., Ashfaq R., Haley B., Perkins S., et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 101 (2004) 9393-9398
75. Sekido Y., Umemura S., Takekoshi S., Suzuki Y., Tokuda Y., Tajima T., et al. Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation. Int J Oncol 22 (2003) 1225-1232
76. Dijkers E.C., de Vries E.G., Kosterink J.G., Brouwers A.H., and Lub-de Hooge M.N. Immunoscintigraphy as potential tool in the clinical evaluation of HER2/neu targeted therapy. Curr Pharm Des 14 (2008) 3348-3362
77. Perik P.J., Lub-de Hooge M.N., Gietema J.A., van der Graaf W.T., de Korte M.A., Jonkman S., et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 24 (2006) 2276-2282
78. 89Zr-trastuzumab for HER2/neu ImmunoPET imaging. J Nucl Med 50 (2009) 974-981
79. Neckers L. Heat shock protein 90: the cancer chaperone. J Biosci 32 (2007) 517-530
80. Solit D.B., Zheng F.F., Drobnjak M., Munster P.N., Higgins B., Verbel D., et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8 (2002) 986-993
81. Zsebik B., Citri A., Isola J., Yarden Y., Szollosi J., and Vereb G. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. Immunol Lett 104 (2006) 146-155
82. Jensen M.R., Schoepfer J., Radimerski T., Massey A., Guy C.T., Brueggen J., et al. NVPAUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res 10 (2008) R33
83. Eccles S.A., Massey A., Raynaud F.I., Sharp S.Y., Box G., Valenti M., et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 68 (2008) 2850-2860
84. Smith-Jones P.M., Solit D.B., Akhurst T., Afroze F., Rosen N., and Larson S.M. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 22 (2004) 701-706
85. Smith-Jones P.M., Solit D., Afroze F., Rosen N., and Larson S.M. Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med 47 (2006) 793-796
86. 89Zr-trastuzumab immunoPET visualizes HER2 downregulation induced by the HSP90 inhibitor NVP-AUY922 in human tumor xenograft. AACR Meeting Abstracts 2009; abstract #3998.
87. Miller K., Wang M., Gralow J., Dickler M., Cobleigh M., Perez E.A., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357 (2007) 2666-2676
88. Nagengast W.B., de Vries E.G., Hospers G.A., Mulder N.H., de Jong J.R., Hollema H., et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 48 (2007) 1313-1319
89. Jayson G.C., Zweit J., Jackson A., Mulatero C., Julyan P., Ranson M., et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 94 (2002) 1484-1493
90. Collingridge D.R., Carroll V.A., Glaser M., Aboagye E.O., Osman S., Hutchinson O.C., et al. The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res 62 (2002) 5912-5919
91. Nagengast W, De Vries E, Warnders F, Hospers G, Mulder N, de Jong J, et al. In vivo VEGF imaging with an anti-VEGF Fab-fragment in a human ovarian tumor xenograft model using MicroPET and MicroCT. AACR Meeting Abstracts 2008; abstract #3161.
92. Nagengast W.B., Lub-de Hooge M.N., Hospers G.A., Brouwers A.H., Hoekstra H.J., Elsinga P.H., et al. Towards clinical VEGF imaging using the anti-VEGF antibody bevacizumab and Fab-fragment ranibizumab. J Clin Oncol 26 (2008) abstract #3547
93. Brown M.L., Houn F., Sickles E.A., and Kessler L.G. Screening mammography in community practice: positive predictive value of abnormal findings and yield of follow-up diagnostic procedures. AJR Am J Roentgenol 165 (1995) 1373-1377
94. Kerlikowske K., Grady D., Barclay J., Sickles E.A., Eaton A., and Ernster V. Positive predictive value of screening mammography by age and family history of breast cancer. JAMA 270 (1993) 2444-2450
95. Lidbrink E., Elfving J., Frisell J., and Jonsson E. Neglected aspects of false positive findings of mammography in breast cancer screening: analysis of false positive cases from the Stockholm trial. BMJ 312 (1996) 273-276
96. Viacava P., Naccarato A.G., Bocci G., Fanelli G., Aretini P., Lonobile A., et al. Angiogenesis and VEGF expression in pre-invasive lesions of the human breast. J Pathol 204 (2004) 140-146
97. Kenny L.M., Coombes R.C., Oulie I., Contractor K.B., Miller M., Spinks T.J., et al. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med 49 (2008) 879-886
98. Beer A.J., Niemeyer M., Carlsen J., Sarbia M., Nahrig J., Watzlowik P., et al. Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET. J Nucl Med 49 (2008) 255-259
99. Schneider B.P., Winer E.P., Foulkes W.D., Garber J., Perou C.M., Richardson A., et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 14 (2008) 8010-8018
100. Bauer K.R., Brown M., Cress R.D., Parise C.A., and Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109 (2007) 1721-1728
101. Mersin H., Yildirim E., Berberoglu U., and Gulben K. The prognostic importance of triple negative breast carcinoma. Breast 17 (2008) 341-346
102. Cleator S., Heller W., and Coombes R.C. Triple-negative breast cancer: therapeutic options. Lancet Oncol 8 (2007) 235-244
103. Cai W., Niu G., and Chen X. Multimodality imaging of the HER-kinase axis in cancer. Eur J Nucl Med Mol Imaging 35 (2008) 186-208
104. Law J.H., Habibi G., Hu K., Masoudi H., Wang M.Y., Stratford A.L., et al. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68 (2008) 10238-10246
105. Cornelissen B., McLarty K., Kersemans V., and Reilly R.M. The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of (111)In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin). Nucl Med Biol 35 (2008) 645-653
106. Massague J. TGFbeta in cancer. Cell 134 (2008) 215-230
107. Bhardwaj B., Klassen J., Cossette N., Sterns E., Tuck A., Deeley R., et al. Localization of platelet-derived growth factor beta receptor expression in the periepithelial stroma of human breast carcinoma. Clin Cancer Res 2 (1996) 773-782
108. Cristofanilli M., Morandi P., Krishnamurthy S., Reuben J.M., Lee B.N., Francis D., et al. Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. Ann Oncol 19 (2008) 1713-1719
109. Jechlinger M., Sommer A., Moriggl R., Seither P., Kraut N., Capodiecci P., et al. Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest 116 (2006) 1561-1570
110. Beljaars L., Weert B., Geerts A., Meijer D.K., and Poelstra K. The preferential homing of a platelet derived growth factor receptor-recognizing macromolecule to fibroblast-like cells in fibrotic tissue. Biochem Pharmacol 66 (2003) 1307-1317
111. van de Ven S.M., Elias S.G., van den Bosch M.A., Luijten P., and Mali W.P. Optical imaging of the breast. Cancer Imaging 8 (2008) 206-215